<code id='6E1D1974E4'></code><style id='6E1D1974E4'></style>
    • <acronym id='6E1D1974E4'></acronym>
      <center id='6E1D1974E4'><center id='6E1D1974E4'><tfoot id='6E1D1974E4'></tfoot></center><abbr id='6E1D1974E4'><dir id='6E1D1974E4'><tfoot id='6E1D1974E4'></tfoot><noframes id='6E1D1974E4'>

    • <optgroup id='6E1D1974E4'><strike id='6E1D1974E4'><sup id='6E1D1974E4'></sup></strike><code id='6E1D1974E4'></code></optgroup>
        1. <b id='6E1D1974E4'><label id='6E1D1974E4'><select id='6E1D1974E4'><dt id='6E1D1974E4'><span id='6E1D1974E4'></span></dt></select></label></b><u id='6E1D1974E4'></u>
          <i id='6E1D1974E4'><strike id='6E1D1974E4'><tt id='6E1D1974E4'><pre id='6E1D1974E4'></pre></tt></strike></i>

          entertainment

          entertainment

          author:comprehensive    Page View:96178
          Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals. -- biotech coverage from STAT
          Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals in San Diego. Sandy Huffaker for STAT

          A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

          In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo, meeting the primary endpoints for these studies and the expectations of market analysts. But the experimental therapy didn’t relieve pain better than a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint observers had been waiting on. And in the bunionectomy trial, the opioid comparator outperformed VX-548 at soothing pain.

          advertisement

          The drug, a small molecule known as VX-548, blocks pain-sensing neurons from signaling the pain without the addictive potential of opioids. It was generally safe, with fewer patients on VX-548 reporting adverse events than those taking the placebo.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          ReNAgade cuts staff seven months after raising $300 million
          ReNAgade cuts staff seven months after raising $300 million

          AdobeBiotechstartupReNAgadeTherapeuticsiscuttingstaffjustsevenmonthsafterraisingthelargestSeriesArou

          read more
          In Memoriam: Notable people who died in 2023
          In Memoriam: Notable people who died in 2023

          1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

          read more

          O'Shea Sibley was killed after expressing queer joy by voguing, activists say

          3:10QueenJean,ofTrans-Liberation,speaksduringavigiltomemorializeO'ShaeSibleyatagasstation,Aug.4,2023